| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Raddeanoside R8 has been studied for its potential anti-inflammatory, anticancer, and immunomodulatory activities. Its structural complexity makes it valuable for exploring saponin-related mechanisms. It may target inflammatory pathways and cancer cell signaling.
|
|---|---|
| ln Vitro |
In vitro, Raddeanoside R8 has anti-inflammatory, anticancer, and immunomodulatory activities. It inhibits cancer cell proliferation and modulates immune responses. Detailed in vitro data including IC50 values are limited. It is used in natural product-based therapeutic research.
|
| ln Vivo |
In vivo studies for Raddeanoside R8 are limited. Its anti-inflammatory and anticancer activities suggest potential therapeutic applications. Animal studies are needed to confirm its in vivo efficacy and safety. Traditional use in Chinese medicine supports its potential benefits.
|
| Enzyme Assay |
Cell-free assays for Raddeanoside R8: anti-inflammatory activity is assessed by measuring inhibition of COX-2 or LOX enzyme activities. Anticancer activity is evaluated using cell-free systems such as enzyme inhibition assays (e.g., topoisomerase inhibition). Immunomodulatory activity is assessed by measuring cytokine levels in cell-free systems.
|
| Cell Assay |
Cellular assays for Raddeanoside R8: cancer cell lines and immune cells are cultured and treated with Raddeanoside R8 at concentrations of 0.1-100 µM for 24-72 hours. Cell viability is measured by MTT assay. Apoptosis is assessed by Annexin V/PI staining. Cytokine production is measured by ELISA. Inflammatory markers are assessed by Western blot or qPCR.
|
| Animal Protocol |
In vivo animal studies for Raddeanoside R8: animal models of inflammation and cancer would be used. Animals are administered Raddeanoside R8 orally or intraperitoneally at doses of 10-50 mg/kg. Inflammatory markers, tumor growth, and immune cell function are assessed. Traditional use in Chinese medicine provides a basis for efficacy studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Raddeanoside R8: as a large saponin with molecular weight 1367.53, it may have very poor oral bioavailability. It is likely metabolized by intestinal flora and liver enzymes. Tissue distribution and elimination pathways are not well characterized.
|
| Toxicity/Toxicokinetics |
Toxicity of Raddeanoside R8: comprehensive toxicity data are limited. As a saponin, it may have hemolytic activity and gastrointestinal effects at high doses. It is for research use only and not approved for clinical use.
|
| References | |
| Additional Infomation |
Raddeanoside R8 is a research compound with potential applications in anti-inflammatory, anticancer, and immunomodulatory research. It is available as a reference standard for pharmacological studies. Its mechanism involves anti-inflammatory and anticancer activities. No clinical trials or FDA approvals have been reported.
|
| Molecular Formula |
C65H106O30
|
|---|---|
| Molecular Weight |
1367.52
|
| Exact Mass |
1366.676
|
| CAS # |
124961-61-1
|
| Appearance |
White to off-white solid
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.641
|
| LogP |
3.86
|
| SMILES |
OC[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O)[C@@H](O)[C@H](OC[C@@H]2[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC([C@@]34CC[C@]5(C)C(=CC[C@@H]6[C@]7(CC[C@H](O[C@H]8[C@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O%10)[C@@H](O)[C@H](O)[C@@H](CO)O9)[C@@H](O)[C@@H](O)CO8)C(C)(C)[C@@H]7CC[C@]65C)C)[C@@H]3CC(C)(C)CC4)=O)O2)O1
|
| InChi Key |
WZEVPZVUDJNKHG-WJNUHIPTSA-N
|
| InChi Code |
InChI=1S/C65H106O30/c1-25-36(69)41(74)46(79)54(86-25)92-50-31(22-67)89-53(49(82)45(50)78)85-24-32-40(73)43(76)48(81)56(90-32)95-59(83)65-18-16-60(3,4)20-28(65)27-10-11-34-62(7)14-13-35(61(5,6)33(62)12-15-64(34,9)63(27,8)17-19-65)91-57-51(38(71)29(68)23-84-57)94-58-52(44(77)39(72)30(21-66)88-58)93-55-47(80)42(75)37(70)26(2)87-55/h10,25-26,28-58,66-82H,11-24H2,1-9H3/t25-,26-,28-,29-,30+,31+,32+,33-,34+,35-,36-,37-,38-,39+,40+,41+,42+,43-,44-,45+,46+,47+,48+,49+,50+,51+,52+,53+,54-,55-,56-,57-,58-,62-,63+,64+,65-/m0/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-[(2S,3R,4S,5S)-3-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7313 mL | 3.6563 mL | 7.3125 mL | |
| 5 mM | 0.1463 mL | 0.7313 mL | 1.4625 mL | |
| 10 mM | 0.0731 mL | 0.3656 mL | 0.7313 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
